## Kent F Hoskins

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1778657/publications.pdf

Version: 2024-02-01

516710 552781 52 713 16 26 h-index citations g-index papers 52 52 52 1255 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	Validation of a tool for identifying women at high risk for hereditary breast cancer in populationâ€based screening. Cancer, 2006, 107, 1769-1776.	4.1	80
2	Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancer–Specific Mortality Among US Women. JAMA Oncology, 2021, 7, 370.	7.1	64
3	Genetic Counseling and Testing in a Community Setting: Quality, Access, and Efficiency. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e34-e44.	3 <b>.</b> 8	56
4	Potassium channel activity controls breast cancer metastasis by affecting $\hat{l}^2$ -catenin signaling. Cell Death and Disease, 2019, 10, 180.	6.3	51
5	4R program results in breast cancer: The impact of 4R Care Delivery Model on timing and sequence of guideline recommended care Journal of Clinical Oncology, 2020, 38, 15-15.	1.6	42
6	Efficacy of a Weight Loss Intervention for African American Breast Cancer Survivors. Journal of Clinical Oncology, 2017, 35, 2820-2828.	1.6	41
7	The influence of neighborhood socioeconomic status and race on survival from ovarian cancer: a population-based analysis of Cook County, Illinois. Annals of Epidemiology, 2015, 25, 556-563.	1.9	38
8	Polypharmacy and Adherence to Adjuvant Endocrine Therapy for Breast Cancer. Journal of Oncology Practice, 2017, 13, e451-e462.	2.5	37
9	Racial disparity in survival from estrogen and progesterone receptor-positive breast cancer: implications for reducing breast cancer mortality disparities. Breast Cancer Research and Treatment, 2017, 163, 321-330.	2.5	34
10	Associations between diabetes medication use and risk of second breast cancer events and mortality. Cancer Causes and Control, 2015, 26, 1065-1077.	1.8	31
11	Impact of a False-Positive Screening Mammogram on Subsequent Screening Behavior and Stage at Breast Cancer Diagnosis. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 397-403.	2.5	27
12	Racial and Ethnic Disparity in Symptomatic Breast Cancer Awareness despite a Recent Screen: The Role of Tumor Biology and Mammography Facility Characteristics. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1599-1606.	2.5	21
13	Selenium levels in human breast carcinoma tissue are associated with a common polymorphism in the gene for SELENOP (Selenoprotein P). Journal of Trace Elements in Medicine and Biology, 2017, 39, 227-233.	3.0	19
14	The effect of neighborhood-level socioeconomic status on racial differences in ovarian cancer treatment in a population-based analysis in Chicago. Gynecologic Oncology, 2014, 135, 285-291.	1.4	18
15	Breast Cancer Risk Assessment Among Low-Income Women of Color in Primary Care: A Pilot Study. Journal of Oncology Practice, 2015, 11, e460-e467.	2.5	18
16	A feasibility study of breast cancer genetic risk assessment in a federally qualified health center. Cancer, 2018, 124, 3733-3741.	4.1	17
17	Measures of economic advantage associated with HPV-positive head and neck cancers among non-Hispanic black and white males identified through the National Cancer Database. Cancer Epidemiology, 2017, 48, 1-7.	1.9	16
18	Association of Population Screening for Breast Cancer Risk With Use of Mammography Among Women in Medically Underserved Racial and Ethnic Minority Groups. JAMA Network Open, 2021, 4, e2123751.	5.9	16

#	Article	IF	CITATIONS
19	Development of a culturally sensitive narrative intervention to promote genetic counseling among African American women at risk for hereditary breast cancer. Cancer, 2021, 127, 2535-2544.	4.1	15
20	Mixed lineage kinase 3 inhibition induces T cell activation and cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 7961-7970.	7.1	13
21	Impact of socioeconomic status and rurality on cancer-specific survival among women with de novo metastatic breast cancer by race/ethnicity. Breast Cancer Research and Treatment, 2022, 193, 707-716.	2.5	11
22	Associations between frailty and cancer-specific mortality among older women with breast cancer. Breast Cancer Research and Treatment, 2021, 189, 769-779.	2.5	10
23	Rationalized inhibition of mixed lineage kinase 3 and CD70 enhances life span and antitumor efficacy of CD8 <sup>+</sup> T cells., 2020, 8, e000494.		9
24	Descriptive characteristics of prostate cancer in patients with a history of primary male breast cancer $\hat{a} \in \text{``a SEER analysis. BMC Cancer, 2017, 17, 659.}$	2.6	8
25	Disparities within luminal breast cancer: Clinical and molecular features of African American and non-Hispanic white patients Journal of Clinical Oncology, 2021, 39, 1009-1009.	1.6	4
26	The association between physical health-related quality of life, physical functioning, and risk of contralateral breast cancer among older women. Breast Cancer, 2022, 29, 287-295.	2.9	4
27	Population-based recurrence rates among older women with HR-positive, HER2-negative early breast cancer: Clinical risk factors, frailty status, and differences by race. Breast, 2021, 59, 367-375.	2.2	3
28	Molecular characterization of luminal breast tumors in African American women Journal of Clinical Oncology, 2021, 39, 550-550.	1.6	2
29	Evaluation of the Novel 4R Oncology Care Planning Model in Breast Cancer: Impact on Patient Self-Management and Care Delivery in Safety-Net and Non–Safety-Net Centers. JCO Oncology Practice, 2021, 17, e1202-e1214.	2.9	2
30	Population screening to identify women at risk for hereditary breast cancer syndromes: The path forward or the road not taken?. Cancer, 2021, , .	4.1	1
31	Racial/Ethnic Differences in the 21-Gene Recurrence Score Assay Among Women With Breast Cancer—Reply. JAMA Oncology, 2021, 7, 1248.	7.1	1
32	4R program results: What is the impact of 4R care delivery model on patient self-management and which patients benefited?. Journal of Clinical Oncology, 2020, 38, 139-139.	1.6	1
33	4R Care Delivery Program results: Impact of implementation metrics on patient self-management and 4R usefulness Journal of Clinical Oncology, 2020, 38, 225-225.	1.6	1
34	Healthcare Predictors of Information Dissemination About Genetic Risks. Cancer Control, 2022, 29, 107327482211046.	1.8	1
35	Pilot study of a culturally sensitive intervention to promote genetic counseling for breast cancer risk. BMC Health Services Research, 2022, 22, .	2.2	1
36	If you don't measure it, you can't improve it: Success and shortcomings of genomic assays in early breast cancer. Cancer, 2020, 126, 3922-3925.	4.1	0

3

#	Article	IF	CITATIONS
37	Deep proteomic analysis of plasma exosomes in patients with advanced, hormone receptor-positive breast cancer treated with palbociclib and tamoxifen Journal of Clinical Oncology, 2021, 39, 1030-1030.	1.6	O
38	Multi-gene prognostic assays and age-related differences in prediction of pathologic complete response to neoadjuvant chemotherapy and survival in breast cancer Journal of Clinical Oncology, 2021, 39, 591-591.	1.6	0
39	What accounts for the racial disparity in survival from estrogen receptor-positive, axillary node-negative breast cancer in the United States? An analysis of the SEER-Oncotype database Journal of Clinical Oncology, 2021, 39, 6534-6534.	1.6	0
40	A single-arm phase II trial of palbociclib in combination with tamoxifen as first-line therapy for metastatic hormone receptor-positive breast cancer Journal of Clinical Oncology, 2021, 39, 1056-1056.	1.6	0
41	Multi-gene hereditary cancer testing among men with breast cancer Journal of Clinical Oncology, 2017, 35, 1532-1532.	1.6	0
42	Family history of breast cancer in non- <i>BRCA</i> male breast cancer: A case-control study Journal of Clinical Oncology, 2017, 35, e13032-e13032.	1.6	0
43	Mammography adherence among medically underserved women undergoing cancer genetic risk assessment Journal of Clinical Oncology, 2020, 38, 1554-1554.	1.6	0
44	Promoting genetic counseling among African American women with hereditary risk for breast cancer Journal of Clinical Oncology, 2020, 38, e13639-e13639.	1.6	0
45	4R Care Delivery Program results: Impact of implementation metrics on patient self-management and 4R usefulness Journal of Clinical Oncology, 2020, 38, e14039-e14039.	1.6	0
46	4R Program results in breast cancer: the impact of 4R Care Delivery Model on timing and sequence of guideline recommended care Journal of Clinical Oncology, 2020, 38, 573-573.	1.6	0
47	4R Program results: What is the impact of 4R care delivery model on patient self-management and which patients benefited?. Journal of Clinical Oncology, 2020, 38, e19211-e19211.	1.6	0
48	Abstract P3-14-11: Mammaprint and Blueprint identify genomic differences in HR+ HER2- breast cancers from young Black and White women. Cancer Research, 2022, 82, P3-14-11-P3-14-11.	0.9	0
49	Abstract P3-14-02: Racial/ethnic differences in the benefit of adjuvant chemotherapy for breast cancer patients with an intermediate risk 21-gene recurrence score. Cancer Research, 2022, 82, P3-14-02-P3-14-02.	0.9	0
50	Impact of time to distant recurrence on breast cancer-specific mortality in hormone receptor-positive breast cancer. Cancer Causes and Control, 2022, , 1.	1.8	0
51	Understanding Racial and Ethnic Inequities in Uptake and Outcomes Following Multigene Prognostic Testing in Early Breast Cancer: The Promise of Real-World Data. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 704-706.	2.5	0
52	Physical functioning, frailty and risks of locally-advanced breast cancer among older women. Breast, 2022, 64, 19-28.	2.2	O